WO1994029452A3 - Enzymatic rna molecules and their application in the treatment of fibrosis and fibrous tissue disease - Google Patents

Enzymatic rna molecules and their application in the treatment of fibrosis and fibrous tissue disease Download PDF

Info

Publication number
WO1994029452A3
WO1994029452A3 PCT/US1994/006331 US9406331W WO9429452A3 WO 1994029452 A3 WO1994029452 A3 WO 1994029452A3 US 9406331 W US9406331 W US 9406331W WO 9429452 A3 WO9429452 A3 WO 9429452A3
Authority
WO
WIPO (PCT)
Prior art keywords
fibrosis
treatment
tissue disease
application
enzymatic rna
Prior art date
Application number
PCT/US1994/006331
Other languages
French (fr)
Other versions
WO1994029452A2 (en
Inventor
Kenneth G Draper
Original Assignee
Ribozyme Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribozyme Pharm Inc filed Critical Ribozyme Pharm Inc
Priority to AU70538/94A priority Critical patent/AU7053894A/en
Publication of WO1994029452A2 publication Critical patent/WO1994029452A2/en
Publication of WO1994029452A3 publication Critical patent/WO1994029452A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

An enzymatic RNA molecule which cleaves mRNA associated with development or maintenance of fibrous or connective tissue disease.
PCT/US1994/006331 1993-06-09 1994-06-02 Enzymatic rna molecules and their application in the treatment of fibrosis and fibrous tissue disease WO1994029452A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU70538/94A AU7053894A (en) 1993-06-09 1994-06-02 Enzymatic rna molecules and their application in the treatment of fibrosis and fibrous tissue disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7434393A 1993-06-09 1993-06-09
US08/074,343 1993-06-09

Publications (2)

Publication Number Publication Date
WO1994029452A2 WO1994029452A2 (en) 1994-12-22
WO1994029452A3 true WO1994029452A3 (en) 1995-02-02

Family

ID=22119047

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/006331 WO1994029452A2 (en) 1993-06-09 1994-06-02 Enzymatic rna molecules and their application in the treatment of fibrosis and fibrous tissue disease

Country Status (2)

Country Link
AU (1) AU7053894A (en)
WO (1) WO1994029452A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6146886A (en) 1994-08-19 2000-11-14 Ribozyme Pharmaceuticals, Inc. RNA polymerase III-based expression of therapeutic RNAs
ES2226414T3 (en) 1998-06-10 2005-03-16 Biognostik Gesellschaft Fur Biomolekulare Diagnostik Mbh STIMULATION OF THE IMMUNE SYSTEM
AU765928B2 (en) * 1999-09-17 2003-10-02 Isis Pharmaceuticals, Inc. Antisense modulation of transforming growth factor-beta expression
US7125660B2 (en) 2000-09-13 2006-10-24 Archemix Corp. Nucleic acid sensor molecules and methods of using same
US20050032683A1 (en) 2000-10-04 2005-02-10 Amento Edward P. Methods of modulating apoptosis by administration of relaxin agonists or antagonists
IL155250A0 (en) * 2000-10-04 2003-11-23 Molecular Medicine Res Inst Methods of modulating apoptosis by administration of relaxin agonists or antagonists
US9758786B2 (en) 2016-02-09 2017-09-12 Autotelic, Llc Compositions and methods for treating pancreatic cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992006693A1 (en) * 1990-10-22 1992-04-30 Fox Chase Cancer Center Dna construct for providing rna therapy
WO1992017206A1 (en) * 1991-03-28 1992-10-15 The Victoria University Of Manchester Wound healing

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992006693A1 (en) * 1990-10-22 1992-04-30 Fox Chase Cancer Center Dna construct for providing rna therapy
WO1992017206A1 (en) * 1991-03-28 1992-10-15 The Victoria University Of Manchester Wound healing

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BECKER, D. ET AL.: "Proliferation o human malignant melanomas is inhibited by antisense oligodeoxynucleotides targeted against basic fibroblast growth factor", THE EMBO JOURNAL, vol. 8, no. 12, 1989, pages 3685 - 3691 *
GRESSNER, A.M.: "Hepatic fibrogenesis: The puzzle of interacting cells, fibrogenic cytokines, regulatory loops, and extracellular matrix molecules", Z.GASTROENTEROL. (SUPPL. 1), vol. 30, 1992, pages 5 - 16 *
WOOLF, T.M. ET AL.: "Specificity of antisense oligonucleotides", PROC.NATL.ACAD.SCI., vol. 89, August 1992 (1992-08-01), pages 7305 - 7309 *

Also Published As

Publication number Publication date
AU7053894A (en) 1995-01-03
WO1994029452A2 (en) 1994-12-22

Similar Documents

Publication Publication Date Title
AU1076101A (en) Enzymes useful for changing the properties of polyester
AU2884695A (en) Modified pseudomonas lipases and their use
EP1700915A3 (en) Enzymatic DNA molecules
EP1621082A3 (en) Process and an enzyme for use in such a process
AU6641596A (en) Improved tft, method of making and matrix displays incorporating the tft
ZA973349B (en) Modulators of molecules with phosphotyrosine recognition units.
FI971530A0 (en) Lipase, the microorganism that produces this, the method of producing the lipase and its use
EP0623171A4 (en) Enzymatic rna molecules.
ZA200102578B (en) Pulveriser and method of pulverising.
BR0112800A (en) Use of a pharmaceutically acceptable bile acid inhibitor and bile acid sequestrant and method for the prevention and treatment of diseases associated with high levels of plasma cholesterol
BR9508323A (en) Use of chitosan and a polysaccharide immobilized in the same chosen from heparin herpan sulfate and extran sulfate and process to prevent or substantially reduce the undesirable adhesion of tissues with respect to wound healing
BR9407971A (en) Pseudodipeptide product chemical and enzymatic process of preparation of the same application as the product and medicine resulting from the application
WO1994029452A3 (en) Enzymatic rna molecules and their application in the treatment of fibrosis and fibrous tissue disease
WO1995013380A3 (en) Method and reagent for treatment of arthritic conditions
WO1998032846A3 (en) Enzymatic nucleic acid treatment of diseases or conditions related to levels of c-fos
AU5874798A (en) Vaccination methods and molecules
DE69621521D1 (en) Cyclodextrin derivatives, their production and use for the introduction of hydrophobic molecules in structured surfactant systems
AU1192797A (en) Oxidase, microorganisms producing the same and use of the same
AU4037000A (en) Method and system for the presentation and redemption of reward offers
AU3965799A (en) Novel molecules of the t125-related protein family and uses thereof
AU1927601A (en) Catalytic RNAs with aminoacylation activity
WO1999023209A3 (en) ErbB-4 TARGETED RIBOZYMES
AU1569700A (en) Novel therapeutic application of low molecular weight heparin
AU2001256845A1 (en) The option system and the option method of an internet advertisement subscription
EP1073471A4 (en) Method of treating endotoxemia

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP KR

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP KR

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA